<DOC>
	<DOCNO>NCT01378377</DOCNO>
	<brief_summary>The research trial test experimental drug MSC1936369B ( Pimasertib ) drug TORISEL , give together , treatment advance solid tumor . The primary purpose study determine maximum tolerate dose recommend Phase II dose ( RP2D ) drug combination .</brief_summary>
	<brief_title>Combination Trial MSC1936369B With Temsirolimus</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Subjects histologically cytologically confirm solid tumor , either refractory standard therapy effective standard therapy available . 2 . Measurable evaluable disease baseline RECIST 1.0 . 3 . Age ≥ 18 year . 4 . Subject read understands informed consent form willing able give inform consent . 5 . Performance Status score ≤ 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . 6 . Women childbearing potential must negative blood pregnancy test screen visit . 7 . Female subject childbearing potential male subject female partner childbearing potential must willing avoid pregnancy use adequate method contraception 2 week prior screen , trial 3 month last dose trial medication . Additional inclusion criterion also apply . 1 . The subject previously treat mTOR inhibitor MEK inhibitor take treatment due drugrelated adverse event . 2 . The subject receive following : Chemotherapy , immunotherapy , hormonal therapy , biologic therapy , investigational agent anticancer therapy within 28 day ( 6 week nitrosoureas mitomycin C ) Day 1 trial treatment ; noncytotoxic chemotherapy investigational agent limit potential delayed toxicity permit terminate least 5 halflives prior Day 1 trial treatment . Extensive prior radiotherapy 30 % bone marrow reserve , prior bone marrow/stem cell transplantation . 3 . The subject recover toxicity due prior therapy baseline Common Terminology Criteria Adverse Events ( CTCAE v4.0 ) Grade 1 less ( except alopecia ) . 4 . The subject poor organ marrow function 5 . History CNS metastases primary CNS tumor , unless subject previously treat condition , asymptomatic requirement anticonvulsant high dose corticosteroid minimum 2 week prior entry trial . 6 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month Day 1 trial drug treatment . 7 . Recent major surgery trauma ( within last 28 day ) , unhealing/open wound , diabetic ulcer , recent drainage significant volume ascites pleural effusion . 8 . History congestive heart failure , unstable angina , myocardial infarction , symptomatic cardiac conduction abnormality , pacemaker , clinically significant cardiac disease history stroke within 3 month prior enter trial . 9 . Baseline correct QT interval screen electrocardiogram ( ECG ) ( QTc ) ≥ 460 m leave ventricular ejection fraction ( LVEF ) &lt; 40 % screen echocardiogram . 10 . Other uncontrolled intercurrent diseases 11 . Retinal degenerative disease ( hereditary retinal degeneration agerelated macular degeneration ) , history uveitis history retinal vein occlusion , medically relevant abnormal ophthalmology assessment screen . 12 . Known suspected allergy MSC1936369B , temsirolimus , rapamycins ( sirolimus , everolimus , etc . ) , excipients , agent give course trial . 13 . Immunization attenuate live vaccine within one week trial entry ( example live vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , etc. ) . 14 . Concomitant use medication substance strong inhibitor inducer CYP3A enzyme , include , limited , phenytoin , carbamazepine , barbiturate , azoles , rifampin , phenobarbital , St. John 's Wort . 15 . Pregnant lactate female . 16 . Legal incapacity limit legal capacity . Additional exclusion criterion also apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Phase I</keyword>
	<keyword>Pimasertib</keyword>
</DOC>